178 related articles for article (PubMed ID: 21729522)
1. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
[TBL] [Abstract][Full Text] [Related]
2. [In vitro selection of single strand deoxyribonucleic acid aptamers binding to cells from patients with acute myeloblastic leukemia].
Zhu P; Wang G; Zhang S; Xu Y; Peng M; Yin H; Chen Y; Tan S; Chen F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 37(8):771-6. PubMed ID: 22954922
[TBL] [Abstract][Full Text] [Related]
3. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
4. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
5. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
6. Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33.
Vercauteren S; Zapf R; Sutherland H
Cytotherapy; 2007; 9(2):194-204. PubMed ID: 17453971
[TBL] [Abstract][Full Text] [Related]
7. [Immunophenotypic features in 143 cases of acute promyelocytic leukemia].
Sun HM; Qian SX; Wu YJ; Qiao C; Hong M; Fan L; Yang H; Zhang JF; Zhang SJ; Wu HX; Qiu HX; Lu H; Xu W; Sheng RL; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):176-9. PubMed ID: 19236773
[TBL] [Abstract][Full Text] [Related]
8. CD34+/CD33+ blast cells: correlation with FAB subtypes.
Rigolin GM; Lanza F; Ferrari L; Castoldi G
Leuk Lymphoma; 1995; 18 Suppl 1():43-8. PubMed ID: 7496354
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
10. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
11. Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)/CD34(+) aptamer.
Zaimy MA; Jebali A; Bazrafshan B; Mehrtashfar S; Shabani S; Tavakoli A; Hekmatimoghaddam SH; Sarli A; Azizi H; Izadi P; Kazemi B; Shojaei A; Abdalaian A; Tavakkoly-Bazzaz J
Cancer Gene Ther; 2016 Sep; 23(9):315-20. PubMed ID: 27514505
[TBL] [Abstract][Full Text] [Related]
12. [Multidrug resistance in acute leukemia].
Takeshita A; Ohno R
Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
[TBL] [Abstract][Full Text] [Related]
13. Differences in CD33 intensity between various myeloid neoplasms.
Jilani I; Estey E; Huh Y; Joe Y; Manshouri T; Yared M; Giles F; Kantarjian H; Cortes J; Thomas D; Keating M; Freireich E; Albitar M
Am J Clin Pathol; 2002 Oct; 118(4):560-6. PubMed ID: 12375643
[TBL] [Abstract][Full Text] [Related]
14. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia.
Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S
Blood; 1992 Apr; 79(7):1811-6. PubMed ID: 1373089
[TBL] [Abstract][Full Text] [Related]
15. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
[TBL] [Abstract][Full Text] [Related]
16. Cellular characteristics of acute leukemia cells simultaneously expressing CD13/CD33, CD7 and CD19.
Mizutani M; Miwa H; Takahashi T; Katoh K; Shikami M; Katayama N; Shiku H; Kita K
Int J Hematol; 1997 Dec; 66(4):479-91. PubMed ID: 9479874
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia.
Lanza F; Rigolin GM; Moretti S; Latorraca A; Castoldi G
Leuk Lymphoma; 1994; 13 Suppl 1():81-5. PubMed ID: 7521238
[TBL] [Abstract][Full Text] [Related]
18. Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery.
Yang M; Jiang G; Li W; Qiu K; Zhang M; Carter CM; Al-Quran SZ; Li Y
J Hematol Oncol; 2014 Jan; 7():5. PubMed ID: 24405684
[TBL] [Abstract][Full Text] [Related]
19. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).
Jiang Y; Xu P; Yao D; Chen X; Dai H
Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288
[TBL] [Abstract][Full Text] [Related]
20. [Immunologic classification used in typing of 68 cases of acute leukemias].
Sun XL; Fang MY; Jiang F; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):39-41. PubMed ID: 16584588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
